High-dose therapy for diffuse large-cell lymphoma in first remission

Annals of Oncology

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Perry, A R ^a   Goldstone, A H ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autologous transplantation; Diffuse large cell lymphoma; High dose therapy; lymphoma; Peripheral blood stem cell transplantation; Prognostic factors

Indexed keywords

BLEOMYCIN A2; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; DRUG MEGADOSE; HUMAN; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031942894     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_1.S9     Document Type: Review

References (41)

1. The NHL Classification Project. A National Cancer Institute sponsored study of classification of NHL. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112-35.
2. Kwak LW, Wilson M, Weiss LM et al. Clinical significance of morphological subdivision in diffuse large-cell lymphoma. Cancer 1991; 68: 1988-93.
3. Armitage JO. The place of third generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. Ann Oncol 1991; 2(Suppl 1): 37-41.
4. Vose JM, Armitage JO. The present status of therapy for patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1991; 2 (Suppl 2): 171-6.
5. Matthews JR, Cooper IA, Matthews JP, Ding JC. Failure of intensive therapy in poor prognosis non-Hodgkin's lymphoma. Aust N Z J Med 1992; 22: 123-8.
6. Bartlett NL, Kwak LW, Horning SJ et al. MACOP-B +/- radiation therapy for diffuse large-cell lymphoma. Analysis of the Stanford results according to prognostic indices. Cancer 1993; 71: 4034-42.
7. Savarese DMF, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumours. J Clin Oncol 1997; 15: 2981-95.
8. S. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med 1995; 333: 1540-5.
9. Philip T, Armitage JO, Spitzer G et al. High dose therapy and ABMT after failure of conventional therapy in adults with inter-mediate grade and high-grade non-Hodgkin's lymphoma. N Engl J Med 1987 316: 1493-8.
10. Gribhen JG, Goldstone AH, Linch DC et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still sensitive to conventional dose therapy. J Clin Oncol 1989; 7: 1621 9.
11. Gisselbrecht C. Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma. Hematol Cell Ther 1996; 38: 297-304.
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
13. Huioun C, Lepage E, Gisselbrecht C et al. Benefit of ABMT over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131-7.
14. Jagannath S, Velasquez WS, Tucker SL et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4 (6): 859-65.
15. Rossi A, Cortelazzo S, Bellavita P et al. Long-term haematological reconstituton following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. Br J Haematol 1997; 96: 620-6.
16. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1722-9.
17. Shipp MA, Neuberg D, Janicek M et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995; 13: 2916-23.
18. Gordon LI, Andersen J, Habermann TM et al. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum tolerated dose of ProMACE-CytaBOM. J Clin Oncol 1996; 4: 1275-81.
19. Aviles A, Delgado S, Nambo MJ et al. Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large-cell lymphoma. Int J Radiat Oncol Biol Phys 1994; 30: 799-803.
20. Press OW, Fisher R, Dalla-Favera R. Aggressive Non-Hodgkin's Lymphomas. ASH Educational Program 1996.
21. Siu LL, Tannock IF. Chemotherapy dose escalation: Case unproven. J Clin Oncol 1997; 15: 2765-8 (Editorial).
22. Velasquez WS, Fuller LM, Jagannath S. Stages I and II diffuse large cell lymphomas: Prognostic factors and long term results with CHOP-Bleo and radiotherapy. Blood 1991; 77: 942-7.
23. Hill ME, MacLennan KE, Cunningham DC et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrandgement in diffuse large cell lymphoma: A British National Lymphoma Investigation study. Blood 1996; 88: 1046-51.
24. Hermine O, Haiuon C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
25. Guglielmi C, Amadori S, Martelli M et al. The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: Long-term results. Ann Oncol 1991; 2: 365-71.
26. Straus DJ, Wong G, Yahalom J et al. Diffuse large cell lymphoma. Prognostic factors with treatment. Leukaemia 1991; 5 (Suppl 1): 32-7.
27. Robertson LE, Redman JR, Butler JJ et al. Discordant bone marrow involvement in diffuse large cell lymphoma: A distinct clinical-pathological entity associated with a continuous risk of relapse. J Clin Oncol 1991; 9: 236-42.
28. Epelbaum R, Faraggi D et al. Survival of diffuse large-cell lymphoma. A multivariate analysis including dose intesity variables. Cancer 1990; 66: 1124-9.
29. Kwak LW, Halpern J, Olshen RA et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma. Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-77.
30. Resegotti L, Vitolo U, Bertini M et al. MACOP-B for advanced stage DLCL. More is better? Italian Multiregional Cooperative Study Group (MCSGL). Leukaemia 1991; 5 (Suppl 1): 86-9.
31. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lynphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211-9.
32. Shipp MA, Harrington DP, Jochelson MS et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with M-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
33. Hoskins PJ, Ng V, Spinelli JJ et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B J Clin Oncol 1991; 9: 220-6.
34. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336 (18): 1290-7.
35. Santini G, Salvagno L, Chiesesi T et al. VACOP-B vs. VACOP-B + autologous BM transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19 (Suppl 1): S154.
36. Baro J, Richard C, Calavia J et al. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's Lymphoma patients with poor prognostic features. Bone Marrow Transplant 1991; 8: 283-9.
37. Nademanee A, Schmidt GH, O'Donnell MR et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor risk aggressive lymphoma: A pilot study. Blood 1992; 80: 1130-4.
38. Jackson GH, Lennard AL, Taylor PRA et al. Autologous bone marrow transplantation in poor risk high-grade non-Hodgkin's lymphoma in first complete remission. Br J Cancer 1994; 70: 501-5.
39. Pettengell R, Radford JA, Morgenstern GR et al. Survival benefit from high dose therapy with autologous blood progenitor cell transplantation in poor prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586-92.
40. Vitolo U, Cartellazzo S, Liberati AM et al. Intensified and high dose chemotherapy with granulocyte colony stimulating factor and autologous stem cell transplantation support as first-line therapy in high-risk diffuse large cell lymphoma. J Clin Oncol 1997; 15: 491-8.
41. Milpied N, Delwail V, Sensebe L et al. sequential high-dose therapy for high-risk intermediate and high-grade adult patients with non-Hodgkin's lymphoma. A pilot study of Goelams group. Bone Marrow Transplant 1997; 19 (Suppl 1): S154.